Xyz historical perspective: Difference between revisions
Jump to navigation
Jump to search
Preeti Singh (talk | contribs) |
Preeti Singh (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Historical Perspective== | |||
===Discovery=== | |||
*[Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event]. | |||
*The association between [important risk factor/cause] and [disease name] was made in/during [year/event]. | |||
*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name]. | |||
*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name]. | |||
==Landmark Events in the Development of Treatment Strategies== | ==Landmark Events in the Development of Treatment Strategies== | ||
Revision as of 18:37, 11 December 2018
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Xyz historical perspective On the Web |
|
American Roentgen Ray Society Images of Xyz historical perspective |
|
Risk calculators and risk factors for Xyz historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Historical Perspective
Discovery
- [Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
- The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
- In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
- In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
Landmark Events in the Development of Treatment Strategies
- In 1997, FDA approved rituximab, to treat patients with B-cell non-Hodgkin lymphoma that did not responds to other treatments.[1]
Impact on Cultural History
Famous Cases
The following are a few famous cases of disease name: